Top 72 medical and healthcare startups in Canada
Dec 22, 2025
|
Like
17
1
Funding: $326.2M
Profound Medical manufactures a device for MRI-guided transurethral ultrasound ablation of the prostate cancer. TULSA-PRO is an FDA/CE-cleared surgical robot for ablation in men with localized prostate cancer, associated with obstructive benign prostatic hyperplasia (BPH), localized recurrent prostate cancer after radiation therapy or large-volume BPH. The system enables preoperative surgical planning, 360-degree guidance, precise and accurate targeting, automatic energy adjustment and real-time temperature monitoring.
Profound Medical manufactures a device for MRI-guided transurethral ultrasound ablation of the prostate cancer. TULSA-PRO is an FDA/CE-cleared surgical robot for ablation in men with localized prostate cancer, associated with obstructive benign prostatic hyperplasia (BPH), localized recurrent prostate cancer after radiation therapy or large-volume BPH. The system enables preoperative surgical planning, 360-degree guidance, precise and accurate targeting, automatic energy adjustment and real-time temperature monitoring.
3
Funding: $887M
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
AbCellera Biologics offers development of antibody therapeutics to improve patient outcomes.
4
Funding: $360.9M
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
5
Funding: $293.4M
AlayaCare delivers an end-to-end home health care software platform and hardware ecosystem for patients.
AlayaCare delivers an end-to-end home health care software platform and hardware ecosystem for patients.
6
Funding: $271.1M
League is a digital health platform that connects people to a comprehensive network of health services and benefits.
League is a digital health platform that connects people to a comprehensive network of health services and benefits.
7
Funding: $267M
Fullscript is a supplement dispensing platform and patient adherence tool that supports practitioners at the point of care and beyond.
Fullscript is a supplement dispensing platform and patient adherence tool that supports practitioners at the point of care and beyond.
8
Funding: $259M
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
9
Funding: $251.7M
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
10
Funding: $236.7M
Deep Genomics brings together world-leading expertise in machine learning and genome biology. We’re inventing a new generation of computational technologies that predict what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic. Our systems predict the molecular effects of genetic variation, opening a new and exciting path to discovery for disease diagnostics and therapies.
Deep Genomics brings together world-leading expertise in machine learning and genome biology. We’re inventing a new generation of computational technologies that predict what will happen within a cell when DNA is altered by genetic variation, whether natural or therapeutic. Our systems predict the molecular effects of genetic variation, opening a new and exciting path to discovery for disease diagnostics and therapies.
11
Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
12
Funding: $196.1M
Aspect Biosystems is an award-winning biotechnology company specializing in 3D bioprinting and tissue engineering. We bring together a multi-talented team of individuals to develop cutting-edge custom human tissue technology for use in the life sciences.
Aspect Biosystems is an award-winning biotechnology company specializing in 3D bioprinting and tissue engineering. We bring together a multi-talented team of individuals to develop cutting-edge custom human tissue technology for use in the life sciences.
13
Funding: $148.3M
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers.
14
Funding: $133M
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
15
Funding: $120.1M
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
16
Funding: $101.6M
Congruence Therapeutics is building a team of 'drug hunters' to go after rare disease targets
Congruence Therapeutics is building a team of 'drug hunters' to go after rare disease targets
17
Funding: $76.8M
Felix is a digital healthcare company providing seamless access to medication through online diagnoses and delivery.
Felix is a digital healthcare company providing seamless access to medication through online diagnoses and delivery.
18
Funding: $71.7M
Maple's mission is to tackle some of the world’s most meaningful issues in healthcare, starting with timely and convenient access to doctors and other healthcare providers – so that you can feel better, faster.
Maple's mission is to tackle some of the world’s most meaningful issues in healthcare, starting with timely and convenient access to doctors and other healthcare providers – so that you can feel better, faster.
19
Funding: $65M
Smile CDR makes it easy for healthcare stakeholders to collect and exchange data with our leading FHIR-based data liberation platform.
Smile CDR makes it easy for healthcare stakeholders to collect and exchange data with our leading FHIR-based data liberation platform.
20
Funding: $56.1M
Swift Medical develops an app that is able to capture wound care information by waving the smartphone above the injured site in a wand-like fashion.
Swift Medical develops an app that is able to capture wound care information by waving the smartphone above the injured site in a wand-like fashion.
